Biogen Idec misses Street EPS

BIIB reported first quarter 2005 adjusted EPS of $0.30, missing by $0.07 the Street's consensus estimate of $0.37 and down 25% from EPS of $0.40 in the first quarter of 2004. The adjusted figure for the first quarter excludes charges of $0.07 per share for the suspension by BIIB and partner Elan (ELN) of multiple sclerosis (MS) compound Tysabri (see BioCentury, March 7, 2005). First quarter revenues were up 9% to $588 million from $542 million. ...